TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avalo Therapeutics ( (AVTX) ) has shared an update.
On October 10, 2025, Avalo Therapeutics released an updated investor presentation highlighting the potential of their lead compound, AVTX-009, in treating hidradenitis suppurativa (HS). The presentation emphasizes AVTX-009’s superior efficacy and longer dosing intervals compared to existing treatments, positioning it as a promising candidate in a market expected to grow significantly. The ongoing Phase 2 LOTUS trial is expected to yield topline data by mid-2026, which could impact Avalo’s market position and stakeholder interests positively.
The most recent analyst rating on (AVTX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
The overall stock score for Avalo Therapeutics is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Despite positive technical indicators suggesting bullish momentum, the negative valuation metrics due to ongoing losses weigh heavily on the stock’s attractiveness.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics operates in the biopharmaceutical industry, focusing on developing novel therapies for immune-mediated inflammatory diseases. Their primary product is AVTX-009, an anti-IL-1β monoclonal antibody, aimed at treating hidradenitis suppurativa and potentially other inflammatory conditions.
Average Trading Volume: 323,004
Technical Sentiment Signal: Sell
Current Market Cap: $187M
See more data about AVTX stock on TipRanks’ Stock Analysis page.